patients With Chronic Hepatitis B Who Stop Long-term Treatment With Adefovir
Stephanos J. Hadziyannis⁎, ‡, , , Vassilios Sevastianos⁎, Irene Rapti⁎, Dimitrios Vassilopoulos§, Emilia Hadziyannis§
⁎ Department of Medicine and Hepatology, Henry Dunant Hospital, National and Kapodistrian University of Athens, Athens, Greece
§ 2nd Academic Department of Medicine, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece
‡ Molecular Biology Laboratory of the Liver Unit at the Evgenidion Hospital, National and Kapodistrian University of Athens, Athens, Greece
Received 24 January 2012. Accepted 24 May 2012. Available online 31 May 2012.
http://dx.doi.org/10.1053/j.gastro.2012.05.039, How to Cite or Link Using DOI
Permissions & Reprints
View full text
Background & Aims
Little is known about the biochemical and virological effects of stopping long-term nucleos(t)ide analogue therapy for hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB).
We performed a cohort observational study, following 33 HBeAg-negative patients with CHB, undetectable serum HBV DNA, and normal levels of aminotransferases after long-term (4 or 5 years) treatment with adefovir dipivoxil (ADV). All patients were followed for 5.5 years; follow-up visits included measurements of serum alanine aminotransferase (ALT), hepatitis B surface antigen (HBsAg), and HBV DNA monthly for the first 6 months and every 3–6 months thereafter. Various factors were measured at baseline, the end of treatment (EOT), and following treatment to identify those associated with clearance of HBsAg.
During the first few months of the postdiscontinuation period, all patients experienced virological and 25 (76%) had biochemical relapse. During the follow-up period, 18 patients (55%) who had discontinued antiviral therapy achieved sustained response (HBV DNA level <2000 IU/L, persistently normal level of ALT). Among these, 13 (72%) cleared HBsAg. Fifteen patients (45%) with virological and/or biochemical relapse were re-treated with oral antiviral agents (11 during the first 18 months and 4 after the third year), without evidence of liver decompensation; only 1 lost HBsAg (6%). Higher pretreatment and EOT levels of ALT, no previous treatment with interferon, and lower level of HBsAg at the EOT were significantly associated with HBsAg clearance based on multivariate analysis.
In HBeAg-negative patients with CHB, it is safe and effective to discontinue ADV therapy after 4 or 5 years; 55% of patients have sustained responses, and 39% of patients lose HBsAg.
another interesting thing, relapsers had low hbvdna, normal ast-alt and did not clear hbsag while clearers had abnormal alt but not too high and high hbvdna
i think adefovir and tenofovir probably even better rescue immune cells, these cells need high hbvdna to mount an immune response shown by abnormal alt mostly 40-80 and declining hbsag.
if ast alt stay normal and hbvdn low or und there is no immune response, this is probably what makes antivirals failure to clear hbv.
another strategy, which actually was mentioned in pisa, is long term nucs then intf add on to nucs and then on and off nucs during intf according to alt-hbsag response
It seems that after achieving undetectable viral load for several years using NA, patients can stop. Three outcomes are possible:
1. Patients clear HbsAg
2. Patients retain low viral load and normal ALT
3. Patients need re-treatment with NA.
It seems all patients after stopping NA, have virological breakthrough (increase in viral load) and 76% have biochemical relapse (increase in ALT). So the trick is: how do doctors and patients decide who should be re-treated or who should wait, and when? After all roughly 50% do not require re-treatment.
And as you suggested, will treatment with Interferon improves the rate of HbsAg clearance? again the question is: who and when?
Low HbsAg level at end of treatment seems to be a good marker - we will need some numbers.
its all in the charts, they compare relapsers vs clearers and all those with alt increase have declining hbsag.
who should be re-treated or who should wait, and when?
those with normal alt, no hbsag decline and high hbvdna need retreat.download the charts and enlarge, the big difference between the two groups is normal alt in relapsers and increased alt in clearers, alt/hbsag is what to look for
it is chart B they reached hbsag 0.01iu/ml, not indicated if also developped hbsab.
i did not consider the abstract because as usual numbers and percentages are not clear, we need full article to make percentages of patients who cleared and those who dont.
we know for sure they were 33 patients hbeag neg, 4-5 years adv and 13 of these 33 got hbsag und
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.